Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice

[1]  B. Watkins,et al.  Docosahexaenoyl ethanolamide improves glucose uptake and alters endocannabinoid system gene expression in proliferating and differentiating C2C12 myoblasts , 2014, Front. Physiol..

[2]  J. Newman,et al.  Lipid Profiling following Intake of the Omega 3 Fatty Acid DHA Identifies the Peroxidized Metabolites F4-Neuroprostanes as the Best Predictors of Atherosclerosis Prevention , 2014, PloS one.

[3]  J. Trygg,et al.  Individual Variation in Lipidomic Profiles of Healthy Subjects in Response to Omega-3 Fatty Acids , 2013, PloS one.

[4]  Dmitry Grapov,et al.  Type 2 Diabetes Associated Changes in the Plasma Non-Esterified Fatty Acids, Oxylipins and Endocannabinoids , 2012, PloS one.

[5]  J. Newman,et al.  Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers[S] , 2012, Journal of Lipid Research.

[6]  B. Watkins,et al.  Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. , 2012, The Journal of nutritional biochemistry.

[7]  K. Kristiansen,et al.  Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity , 2012, Obesity.

[8]  G. Shulman,et al.  Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype. , 2011, Cell metabolism.

[9]  S. Banni,et al.  Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects , 2011, Nutrition & metabolism.

[10]  M. Cascio,et al.  Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. , 2010, Carcinogenesis.

[11]  G. Wallukat,et al.  Arachidonic Acid-metabolizing Cytochrome P450 Enzymes Are Targets of ω-3 Fatty Acids* , 2010, The Journal of Biological Chemistry.

[12]  B. Watkins,et al.  Bone mineral content is positively correlated to n-3 fatty acids in the femur of growing rats , 2010, British Journal of Nutrition.

[13]  E. Schleicher,et al.  Hepatic lipid composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be estimated from plasma VLDL fatty acid ratios. , 2009, Clinical chemistry.

[14]  M. Collu,et al.  Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. , 2009, The Journal of nutrition.

[15]  N. Tennagels,et al.  Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle , 2009, Diabetologia.

[16]  P. Formisano,et al.  The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase , 2008, Molecular Pharmacology.

[17]  D. Cota.  The Role of the Endocannabinoid System in the Regulation of Hypothalamic‐Pituitary‐Adrenal Axis Activity , 2008, Journal of neuroendocrinology.

[18]  F. Karpe,et al.  Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. , 2008, The American journal of clinical nutrition.

[19]  A. Hamsten,et al.  Fatty acid desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance , 2008, Diabetologia.

[20]  G. Wittert,et al.  The expression of receptors for endocannabinoids in human and rodent skeletal muscle. , 2007, Biochemical and biophysical research communications.

[21]  P. Bernante,et al.  The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. , 2007, The Journal of clinical endocrinology and metabolism.

[22]  F. Bermúdez-Silva,et al.  Role of cannabinoid CB2 receptors in glucose homeostasis in rats. , 2007, European journal of pharmacology.

[23]  P. V. Piazza,et al.  Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. , 2007, Diabetes & Metabolism.

[24]  Daoyan Liu,et al.  Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. , 2007, Biochemical and biophysical research communications.

[25]  F. Fezza,et al.  Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. , 2006, Biochimie.

[26]  M. Fasshauer,et al.  Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity , 2006, Diabetes.

[27]  M. Maj,et al.  Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. , 2006, The Journal of clinical endocrinology and metabolism.

[28]  B. Watkins,et al.  Dietary ratio of n-6/n-3 PUFAs and docosahexaenoic acid: actions on bone mineral and serum biomarkers in ovariectomized rats. , 2006, The Journal of nutritional biochemistry.

[29]  F Xavier Pi-Sunyer,et al.  Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.

[30]  D. Cota,et al.  The emerging role of the endocannabinoid system in endocrine regulation and energy balance. , 2006, Endocrine reviews.

[31]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[32]  J. Després,et al.  Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.

[33]  Arya M. Sharma,et al.  Activation of the peripheral endocannabinoid system in human obesity. , 2005, Diabetes.

[34]  D. Hardie,et al.  Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase* , 2005, Journal of Biological Chemistry.

[35]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[36]  M. Stock,et al.  Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice , 2005, International Journal of Obesity.

[37]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[38]  M. Valenti,et al.  Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression , 2004, The Journal of Neuroscience.

[39]  J. Bellenger,et al.  A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  P. Sparling,et al.  Exercise activates the endocannabinoid system , 2003, Neuroreport.

[41]  B. Watkins,et al.  Impact of dietary n−3 FA deficiency on rat bone tissue FA composition , 2003, Lipids.

[42]  J. Girault,et al.  Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus , 2003, The Journal of Neuroscience.

[43]  P. Soubrié,et al.  Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[44]  D. Piomelli,et al.  A Peripheral Mechanism for CB1 Cannabinoid Receptor-Dependent Modulation of Feeding , 2002, The Journal of Neuroscience.

[45]  O. Pedersen,et al.  Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. , 2002, Diabetes.

[46]  T. Bisogno,et al.  Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  B. Watkins,et al.  Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. , 2000, The Journal of nutrition.

[48]  L. Petrocellis,et al.  Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response , 1999, Neuroscience.

[49]  L. Hanuš,et al.  Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. , 1997, Journal of medicinal chemistry.

[50]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[51]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[52]  N. Kaminski,et al.  Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. , 1994, Biochemical pharmacology.

[53]  K. Mackie,et al.  Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Walter Funk,et al.  Molecular biology of myogenic regulatory factors. , 1991, Molecular biology & medicine.

[55]  A. Baron,et al.  Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. , 1988, The American journal of physiology.

[56]  A. Howlett.  Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. , 1985, Molecular pharmacology.

[57]  A. Howlett.  Cannabinoid receptor signaling. , 2005, Handbook of experimental pharmacology.